History
Close timeline
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
2011
2010
2009
2008
2007
2006
2005
2004
2003
2002
2001
2000
1999
1998
1996
1993
20222022
Evotec enters a drug discovery collaboration with Janssen
Evotec adds cell therapy manufacturing facility with acquisition of Rigenerand
Evotec and Almirall enter into a multi-target alliance in medical dermatology
Evotec and Sernova announce partnership for iPSC-based beta cell replacement therapy to advance a 'functional cure' for diabetes
Evotec and BMS extend and expand strategic partnership in protein degradation
Evotec enters iPSC-based drug discovery partnership with Boehringer Ingelheim in ophthalmology
Evotec and Lilly enter into drug discovery collaboration in metabolic diseases
20212021
Evotec announces Bristol Myers Squibb opt-in of EVT8683 as the first programme from iPSC-based neurodegeneration collaboration
Just - Evotec Biologics opens J.POD® 1 US in Redmond, Washington
Positive Phase IIb data for investigational P2X3 antagonist in patients with refractory chronic cough
Evotec launches “beLAB1407” in collaboration with Bristol Myers Squibb
Evotec launches “beLAB2122” in collaboration with Bristol Myers Squibb
Implementation of Action Plan 2025 “The data-driven R&D Autobahn to Cures”
Evotec and Takeda enter strategic RNA targeting drug discovery and development alliance
Evotec and Chinook Therapeutics enter into strategic collaboration to discover and develop novel precision medicines for chronic kidney diseases
Evotec starts clinical development of Chikungunya antibody
20202020
Mubadala Investment Company and Novo Holdings A/S invest € 250 m in Evotec SE
Evotec and Novo Nordisk form strategic alliance to develop novel therapies for kidney diseases
Evotec and Secarna Pharmaceuticals form strategic partnership in the field of antisense therapy
Just - Evotec Biologics to produce monoclonal antibody products against COVID-19 for the Department of Defense
Evotec, Samsara BioCapital, and KCK launch Autobahn Labs
Evotec regains global rights to beta cell replacement therapy
Evotec expands into gene therapy with the dedicated site Evotec GT in Austria
Just – Evotec Biologics initiates construction of first J.POD facility in North America and enters into multi-year collaboration with MSD around facility of the future
Bayer and Evotec form new strategic alliance focusing on polycystic ovary syndrome
20192019
Evotec and Vifor Pharma form joint venture for early development in nephrology
Evotec, Integra Holdings and Yissum establish LAB555
Evotec and Takeda enter collaboration agreement to discover clinical candidates across multiple therapeutic areas
P2X3 antagonist demonstrates efficacy against refractory chronic cough in Phase II (POC)
Evotec and venture capital consortium form "Breakpoint Therapeutics GmbH"
Evotec SE places first Schuldschein (Promissory note) worth € 250 m
Evotec, Sensyne Health, the University of Oxford, OSI, and OUI create new bridge partnership “LAB10x” in digital health
Evotec jump-starts biologics with acquisition of Just Biotherapeutics
Evotec AG is converted into Evotec SE
Evotec receives milestone payment for start of second Phase II trial in its multi-target alliance with Bayer
Evotec and Galapagos enter into collaboration in the field of fibrosis
Evotec reaches important scientific achievement within iPSC-based collaboration with Celgene
20182018
Evotec receives milestone payment for start of Phase II trial in its multi-target alliance with Bayer
Evotec achieves second milestone in diabetes alliance with Sanofi
Evotec and Sanofi sign definitive agreement to combat infectious diseases
Evotec forms academic BRIDGE LAB591 with Arix Bioscience and Fred Hutchinson Cancer Research Center
Evotec and Celgene expand iPSC collaboration to include additional cell lines
Evotec and Celgene enter into strategic oncology partnership
Evotec and Bayer advance third endometriosis programme into Phase I clinical development
Evotec and Sanofi in exclusive talks to create an Evotec-led Infectious Disease open innovation R&D platform
Evotec and APEIRON achieve first milestone in immuno-oncology alliance with Sanofi
20172017
Evotec receives clinical milestone as part of its discovery alliance with Boehringer Ingelheim
Evotec joins forces with academic leaders to accelerate drug discovery in kidney diseases and build NEPLEX
Evotec achieves first milestone in neurodegeneration alliance with Celgene
Evotec invests in Exscientia to advance AI-driven drug discovery
Evotec and MaRS Innovation establish LAB150 in Toronto
European Investment Bank supports Evotec´s Innovate strategy with € 75 m loan
Evotec acquires Aptuit
Evotec and Bayer advance endometriosis programme into Phase I clinical development and extend alliance
Evotec announces strategic investment in Facio Therapies to support development of novel FSHD therapy
Evotec joins NURTuRE consortium to mine unique kidney disease patient biobank
Evotec achieves first milestone in Diabetes alliance (TargetBCD) with Sanofi
Novo A/S becomes new long-term strategic shareholder in Evotec
Evotec and Eternygen to develop novel metabolic disease therapy, Evotec participate in Eternygen's Series A funding
20162016
Multi-year drug discovery collaboration for neurodegenerative diseases with Celgene based on Evotec`s iPSC platform
Evotec acquired Cyprotex, a specialist pre-clinical contract research organisation in ADME-Tox and DMPK headquartered in the UK
Evotec and Oxford University create novel Partnership called 'LAB282'
Evotec and Carrick Therapeutics build strategic alliance, Evotec contributes to funding round
Evotec enters into strategic multi-target alliance with C4X Discovery
Evotec and Bayer partner to develop new treatments to fight kidney diseases
Start of first Phase I within Endometriosis alliance with Bayer
Evotec and Ellersbrook join forces to accelerate development of TargetNASH
Evotec extends integrated drug discovery alliance with Genentech
Evotec and ex scientia announce partnership to discover bispecific small molecule immuno-oncology therapeutics (TargetBiSM)
Position cemented as the world leader in outsourced compound management through new agreements with UCB and Pierre Fabre
Evotec spins off auto-immune disease company as 'Topas Therapeutics GmbH'
Evotec awarded grant from The Michael J. Fox Foundation for Parkinson's Research (TargetaSN)
20152015
Evotec receives important pre-clinical milestones as part of its multi-target alliance with Bayer
Evotec enters into licence and collaboration agreement with Pfizer Inc. in tissue fibrosis (TargetFibrosis)
Evotec and CHDI Foundation expand ongoing collaboration to fight Huntington's disease
Evotec, Apeiron Biologics and Sanofi jointly develop novel small molecule-based cancer immunotherapies (TargetImmuniT)
Sanofi and Evotec align forces to develop next generation therapies in diabetes (TargetBCD)
Evotec's partner Roche announced that Sembragiline (RG1577, EVT302), a MAO-B inhibitor for the treatment of Alzheimer's disease failed to demonstrate benefit on the primary endpoint
Evotec and Sanofi sign definitive agreement for major mulit-component strategic alliance and acquires Sanofi's scientific operations and related employees at Toulouse site
Second Genome and Evotec to collaborate in microbiome discovery and development (TargetMB)
Evotec and Padlock Therapeutics announce initial success and extension of long-term collaboration
20142014
Evotec and CHDI Foundation extend ongoing collaboration to fight Huntington's disease
Termination of the development of DiaPep277® (one of Evotec's advanced partnered pipeline projects) by Hyperion Therapeutics, Inc.
Twenty three milestones achieved as part of the collaboration with Boehringer Ingelheim
Evotec establishes an anti-infectives platform with the acquisition of Euprotec Ltd
Evotec acquires Bionamics GmbH to accelerate EVT Innovate strategy
20132013
Evotec and Yale University to collaborate on cancer therapy (TargetDBR)
Evotec announces TargetAD collaboration with Johnson & Johnson Innovation to identify and develop novel Alzheimer's disease therapies
Evotec and Harvard University to collaborate on exploration of enteroendocrine signals affecting key metabolic pathways (TargetEEM)
Evotec and Harvard Stem Cell Institute form CureMN collaboration to advance ALS research
Evotec and Harvard University to collaborate on development of new class of antibacterials (TargetPGB)
Dana-Farber's Belfer Institute for Applied Cancer Science and Evotec establish collaboration in oncology (TargetKDM)
Evotec extends drug discovery alliance with Genentech
Evotec acquires Cell Culture Service GmbH
Evotec and Apeiron Biologics announce collaboration on cancer immunotherapy (TargetImmuniT)
20122012
Evotec partners its EVT100 series with Janssen Pharmaceuticals
Evotec partners with Haplogen to develop drugs for infectious diseases (TargetPicV)
Evotec extends ongoing collaboration with CHDI Foundation
Evotec and Bayer enter into long-term, multi-target alliance to fight Endometriosis
NIH awards major contract to Evotec to manage and operate a small molecule repository
Evotec and Harvard University enter first academic bridge alliance with Janssen Pharmaceuticals (CureBeta)
Evotec grants exclusive rights on EVT401 in China to CONBA Pharmaceutical
Evotec Action Plan 2016 – Innovation Efficiency
Evotec and Harvard University expand strategic alliance into Kidney Disease (CureNephron)
20112011
Evotec and Roche sign an agreement to develop compound (EVT302) against Alzheimer’s disease
Start of multi-target collaboration with UCB in neurodegenerative and neurological diseases and in the field of immunology
Evotec and Roche to jointly develop biomarkers in oncology
Evotec acquires compound management business from Galapagos and further strengthens its innovation offering
Evotec and Roche decided to voluntarily terminate the first proof-of-concept study in treatment-resistant depression with their NR2B sub-type selective NMDA antagonist EVT101
Evotec acquires Kinaxo, expanding its drug discovery platform with cutting-edge technologies
Evotec establishes research collaboration with Harvard University and the Howard Hughes Medical Institute in diabetes research (CureBeta)
20102010
Evotec entered into a licence and collaboration agreement with MedImmune in the diabetes therapeutic area with a particular focus on the regeneration of insulin producing beta cells
Evotec licenses Phase II insomnia (EVT201) candidate to JingXin Pharma for development in China
Evotec is adding a core capability in metabolic disease biology by acquiring DeveloGen
Start of Phase II with EVT101 (Treatment-resistant depression) in collaboration with Roche
Start of integrated long-term drug discovery alliance with Genentech
Extension of CHDI collaboration
20092009
TecDAX re-entry/Evotec voluntarily delists from NASDAQ
Evotec and Boehringer Ingelheim extend and broaden research collaboration
Start of Phase I with EVT103 (Treatment-resistant depression) in collaboration with Roche
Evotec accelerates growth strategy of its discovery alliance business with acquisition of Indian RSIPL
Successful Completion of first Phase I Study with EVT401 (P2X7)
Evotec acquires Zebrafish Screening Operations of Summit Corporation
Evotec Restructures and Implements Evotec 2012 - Action Plan to Focus and Grow
Evotec and Roche to develop EVT101 for treatment-resistant depression
20082008
Three-year drug discovery collaboration with Novartis
Start Phase I with P2X7 Antagonist (EVT401) in inflammatory disease
Evotec completes acquisition of Renovis, NASDAQ-Listing
20072007
Evotec sells its Chemical Development Business to Aptuit
Evotec and Research Support International Limited form Evotec-RSIL Ltd, a Joint Venture in India for the design, synthesis, management and commercialisation of compound libraries
Positive results in two Phase II trials with EVT201 in insomnia
20062006
Evotec sells Evotec Technologies to PerkinElmer
Start of multi-year drug discovery alliance with CHDI on Huntington disease
Forming a global alliance with Roche to jointly discover and develop compounds in the area of CNS
Extension of global medicinal chemistry agreement and medicinal chemistry collaboration in oncology with Roche
Successful completetion of Phase I for potential Alzheimer's Disease treatment, EVT101
Further expansion and extension of Boehringer Ingelheim drug discovery collaboration
Evotec in-licenses two Phase I MAO-B inhibitor from Roche with disease modifying potential in Alzheimer's Disease
20052005
Capital increase, EUR 28.4 m
Extension of medicinal chemistry agreement with Roche
20042004
Start of multi-year, multi-target drug discovery alliance with Boehringer Ingelheim
Strategic global medicinal chemistry agreement with Roche
Evotec Neurosciences to licence NMDA receptor NR2B subunit selective antagonists from Roche
20032003
Evotec Neurosciences and Takeda enter into a four-year collaboration to identify novel Alzheimer's disease targets
20022002
Spinning off its technology development business into its subsidiary Evotec Technologies
Extension of Discovery Chemistry Agreement with Roche
20012001
Initial service collaborations with Eli Lilly, Merck, Novartis and Roche
20002000
Merge with Oxford Asymmetry International plc, form Evotec OAI AG, to become the leader in the discovery and development of novel small molecule drugs
Successful market introduction of EVOscreen®
19991999
In November, Evotec BioSystems AG goes public
Establishes Evotec Neurosciences GmbH in Hamburg
19981998
Raising DM 46 m (EUR 23.5 m), the largest private placements seen in the European biotech sector
19961996
Collaborations with Novartis and SmithKlineBeecham to develop EVOscreen® (High-Throughput Screening System)
19931993
Evotec BioSystems GmbH was founded in Hamburg, Germany. Among the founders were Nobel Laureate Professor Manfred Eigen, Dr Karsten Henco, Dr Ulrich Aldag, Dr Freimut Leidenberger, Dr Heinrich Schulte, Professor Rudolf Rigler and Dr Charles Weissmann
TOP